CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 40 enrolled
Drug / intervention
Lipid-Based Artificial Tear +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06784661
NCT06784661Phase 4Completed

Immediate Effects of Lipid-Based Artificial Tears (Mineral Oil and Hydroxypropyl Guar) and Non-Lipid Artificial Tears (Hydroxypropyl Guar) on Corneal Aberrations in Healthy Individuals

University of Seville·interventional·Posted Jan 20, 2025·Updated May 4, 2026

In Brief

A Phase 4 clinical trial evaluating Lipid-Based Artificial Tear and Non-Lipid Artificial Tear for Aberration, Corneal Wavefront. Completed, enrolled 40 participants across 1 site.

Detailed Summary

This study evaluates the immediate effects of two types of artificial tear formulations on corneal aberrations in a healthy population. The interventions include a lipid-based formulation containing mineral oil and hydroxypropyl guar, and a non-lipid formulation containing hydroxypropyl guar alone. Participants will receive a single instillation of each formulation in separate eyes, with measurements of corneal aberrations taken before and 15 minutes after instillation. The study aims to compare the optical changes induced by these formulations and assess their impact on the ocular surface quality.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesPortugal
CollaboratorsAlcon Research

Timeline

Phase 4CompletedFinished
20252026
First PostedJan 20, 2025
Enrollment StartFeb 1, 2025
Primary CompletionMar 1, 2025
Study CompletionMar 15, 2025
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 1.4 years ago

Interventions

Lipid-Based Artificial Teardrug

This intervention consists of a lipid-based artificial tear formulation containing mineral oil and hydroxypropyl guar. It is designed to enhance the tear film's lipid layer and improve ocular surface stability. Participants in this group will receive a single drop in each eye, and corneal aberrations will be measured at baseline and 15 minutes after instillation.

Non-Lipid Artificial Teardrug

This intervention consists of a non-lipid artificial tear formulation containing hydroxypropyl guar. It is intended to stabilize the aqueous layer of the tear film and maintain optical quality. Participants in this group will receive a single drop in each eye, and corneal aberrations will be measured at baseline and 15 minutes after instillation.